Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Janet M Leeds"'
Autor:
Genmin Lu, Polly Pine, Janet M Leeds, Francis DeGuzman, Pratikhya Pratikhya, Joyce Lin, John Malinowski, Stanley J Hollenbach, John T Curnutte, Pamela B Conley
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0195122 (2018)
Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors.To eval
Externí odkaz:
https://doaj.org/article/c3fffb687d68400eaeda3f7391af4980
Autor:
Adams Amantana, Yali Chen, Shanthakumar R Tyavanagimatt, Kevin F Jones, Robert Jordan, Jarasvech Chinsangaram, Tove C Bolken, Janet M Leeds, Dennis E Hruby
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61514 (2013)
Plasma pharmacokinetics of ST-246, smallpox therapeutic, was evaluated in mice, rabbits, monkeys and dogs following repeat oral administrations by gavage. The dog showed the lowest Tmax of 0.83 h and the monkey, the highest value of 3.25 h. A 2- to 4
Externí odkaz:
https://doaj.org/article/f4abcb9907704df6be4a8674f410129f
Autor:
Yali Chen, Adams Amantana, Shanthakumar R Tyavanagimatt, Daniela Zima, X Steven Yan, Gopi Kasi, Morgan Weeks, Melialani A Stone, William C Weimers, Peter Samuel, Ying Tan, Kevin F Jones, Daniel R Lee, Shirley S Kickner, Bradley M Saville, Martin Lauzon, Alan McIntyre, Kady M Honeychurch, Robert Jordan, Dennis E Hruby, Janet M Leeds
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23237 (2011)
BackgroundST-246® is an antiviral, orally bioavailable small molecule in clinical development for treatment of orthopoxvirus infections. An intravenous (i.v.) formulation may be required for some hospitalized patients who are unable to take oral med
Externí odkaz:
https://doaj.org/article/b5e19bc34bc24297a5169eda2e119b5a
Autor:
Deborah Siegal, Genmin Lu, Janet M. Leeds, Mark Karbarz, Janice Castillo, Vandana Mathur, Athiwat Hutchaleelaha, Uma Sinha, Michael Kitt, Matt McClure, Stanley J. Hollenbach, John T. Curnutte, Pamela B. Conley, Mark Crowther
Publikováno v:
Blood Advances, Vol 1, Iss 21, Pp 1827-1838 (2017)
Abstract: Direct factor Xa (FXa) inhibitors lack a specific reversal agent for emergencies such as major bleeding or urgent surgery. Andexanet alfa, a modified, catalytically inactive, recombinant human FXa derivative, reverses anticoagulant effect b
Externí odkaz:
https://doaj.org/article/a33f22871e07436596a3936e4cc98e10
Autor:
Pamela B. Conley, John T. Curnutte, Glenn Michelson, Y. Lynn Wang, Jeremy Segal, Pin Lu, Sabah Kadri, Kenneth Der, Janet M. Leeds, Matt Birrell, Anjali Pandey, Andreas Betz, Jiajia Feng, Greg P. Coffey
Purpose:Preclinical studies suggest SYK and JAK contribute to tumor-intrinsic and microenvironment-derived survival signals. The pharmacodynamics of cerdulatinib, a dual SYK/JAK inhibitor, and associations with tumor response were investigated.Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718a86465004bc70185ecc77b0994502
https://doi.org/10.1158/1078-0432.c.6526856
https://doi.org/10.1158/1078-0432.c.6526856
Autor:
Pamela B. Conley, John T. Curnutte, Glenn Michelson, Y. Lynn Wang, Jeremy Segal, Pin Lu, Sabah Kadri, Kenneth Der, Janet M. Leeds, Matt Birrell, Anjali Pandey, Andreas Betz, Jiajia Feng, Greg P. Coffey
Supplemental Appendix (Table S1, Figure S1, Figure S2, Figure S3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b3834997e784594f973dcbbcc292c1e
https://doi.org/10.1158/1078-0432.22468154
https://doi.org/10.1158/1078-0432.22468154
Publikováno v:
Viruses, Vol 2, Iss 11, Pp 2409-2435 (2010)
ST-246 (Tecovirimat) is a small synthetic antiviral compound being developed to treat pathogenic orthopoxvirus infections of humans. The compound was discovered as part of a high throughput screen designed to identify inhibitors of vaccinia virus-ind
Externí odkaz:
https://doaj.org/article/8351d4bf79d846408483ab895a1ef70f
Autor:
Pamela B. Conley, Oliver Grottke, Necib Akman, Till Braunschweig, Markus Honickel, Rolf Rossaint, Janet M. Leeds
Publikováno v:
British Journal of Anaesthesia. 123:186-195
BACKGROUND: Andexanet alfa (andexanet) reverses the anticoagulant effects of factor Xa inhibitors, but it has not been assessed in clinical studies for apixaban reversal in trauma. This study evaluated andexanet for reversing apixaban anticoagulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::811f3107f7aea0e229ce45d2f8a8b5af
https://doi.org/10.1016/j.bja.2019.04.059
https://doi.org/10.1016/j.bja.2019.04.059
Autor:
Mark Karbarz, Vandana Mathur, Gallia Levy, John T. Curnutte, Pamela B. Conley, Genmin Lu, Janice Castillo, Mark Crowther, Janet M. Leeds
As with any anticoagulant, factor Xa (FXa) inhibitors are associated with a risk of major bleeding. Andexanet alfa is a recombinant modified human FXa lacking enzymatic activity, developed for reversal of FXa inhibitor–induced anticoagulation. In t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf6f59aaf5580fbfa62e5ac4f7b7021
https://europepmc.org/articles/PMC7042988/
https://europepmc.org/articles/PMC7042988/
Autor:
Janet M. Leeds, Rosie Z. Yu, Scott P. Henry, Arthur A. Levin, David K. Monteith, Mike V. Templin, Richard S. Geary
Publikováno v:
Biotechnology and Safety Assessment ISBN: 9780367811662
Biotechnology and Safety Assessment
Biotechnology and Safety Assessment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ecc6f7fd3c1fae393653f806bffea9b
https://doi.org/10.1201/9780367811662-7
https://doi.org/10.1201/9780367811662-7